(ser LIP oh nase AL fa)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intraventric [preservative free]:
Brineura: 150 mg/5 mL (1 ea)
Brand Names: U.S.
- Hydrolytic Lysosomal N-terminal Tripeptidyl Peptidase
Use: Labeled Indications
Neuronal ceroid lipofuscinosis type 2: Indicated to delay the loss of ambulation in symptomatic pediatric patients ≥3 years with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2)
Acute intraventricular access device-related complications (eg, leakage, device failure, device-related infection), ventriculoperitoneal shunts
There are no known significant interactions.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience headache. Have patient report immediately to prescriber signs of infection, abnormal heartbeat, tachycardia, bradycardia, severe dizziness, passing out, seizures, irritability, anxiety, or vomiting (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.